BTIG Reiterates Buy Rating on Verastem (VSTM)

BTIG analyst Justin Zelin reiterated a Buy rating and $20.00 price target on Verastem (NASDAQ: VSTM).

The analyst commented: "VSTM reported 4Q earnings. We see VSTM as a unique story in the currently challenging biotech tape, having a drug near commercial approval in an underserved oncology indication with $1B+ market potential and several pipeline catalysts, including in frontline metastatic pancreatic cancer from the RAMP 205 study in mid '25 as well as from their KRASG12D program in 1H25 in NSCLC and pancreatic cancer which could drive additional upside. An update from the RAMP 203 study evaluating avutometinib plus defactinib with a KRASG12Ci is expected at medical meeting in 2H25. Reiterate our Buy rating and $20 PT."

For an analyst ratings summary and ratings history on Verastem click here. For more ratings news on Verastem click here.

Shares of Verastem closed at $6.82 yesterday.

You May Also Be Interested In